AcuityMD Lands $80 Million in New Funding to Fuel AI Innovation in Medical Device (MedTech) Industry

AcuityMD获得8000万美元新融资，推动医疗设备（MedTech）行业AI创新

Nearing $1B valuation and poised for rapid growth, AcuityMD introduces AcuityAI

接近10亿美元估值并有望快速增长，AcuityMD推出AcuityAI

BOSTON, April 21, 2026-- AcuityMD, the AI platform for MedTech, today announced $80 million in new funding to elevate its platform with advanced artificial intelligence (AI) capabilities and drive the company’s mission of accelerating adoption of medical technology. The Series C round was led by existing investor StepStone Group, with additional participation from Benchmark, Redpoint Ventures, ICONIQ, and Atreides Management.

波士顿，2026年4月21日——医疗科技领域的人工智能平台AcuityMD今天宣布获得8000万美元的新融资，以通过先进的人工智能（AI）能力提升其平台，并推动公司加速医疗技术应用的使命。此C轮融资由现有投资者StepStone Group领投，Benchmark、Redpoint Ventures、ICONIQ和Atreides Management也参与其中。

Now supporting 16 of the top 20 MedTech companies and having helped customers identify over $34 billion in pipeline, AcuityMD has raised more than $160 million to date and is valued at $955 million..

目前，AcuityMD已支持前20大医疗技术公司中的16家，并帮助客户发现了超过340亿美元的潜在业务，迄今为止已筹集超过1.6亿美元资金，估值达9.55亿美元。

“AcuityMD is scaling rapidly while continuing to invest thoughtfully in its people and platform,” said Hunter Somerville, Partner at StepStone Group. “The depth of the company’s data provides a meaningful advantage, and as AI capabilities continue to advance, that foundation becomes more valuable. We also see significant opportunities for AcuityMD to benefit the broader MedTech organization beyond commercial, reinforcing our decision to deepen our commitment.”.

“AcuityMD在快速扩展的同时，继续对其员工和平台进行深思熟虑的投资，”StepStone Group合伙人亨特·萨默维尔表示。“公司数据的深度提供了显著的优势，随着人工智能能力的不断提升，这一基础变得更有价值。我们还认为，AcuityMD除了在商业领域之外，还有巨大的机会惠及更广泛的医疗科技组织，这进一步巩固了我们加深承诺的决定。”

MedTech companies face mounting pressure not only to successfully launch innovations, but also to capture and grow market share in an environment that can shift abruptly. Portfolio changes, hospital consolidation, regulatory fluctuation, and reimbursement updates can upend the competitive landscape faster than any sales representative or leader can track on their own..

医疗器械公司不仅面临着成功推出创新产品的压力，还面临着在可能瞬息万变的环境中获取并扩大市场份额的挑战。产品组合的变化、医院整合、监管波动以及报销政策更新，都可能迅速颠覆竞争格局，其速度之快以至于任何销售代表或领导者都无法独自追踪。

AcuityMD was built to solve the root cause of the problem: the commercial insights MedTech companies need are scattered across claims databases, FDA filings, government records, and market signals that no single MedTech company can assemble alone. AcuityMD aggregates all of it into a proprietary MedTech ontology: a continuously enriched knowledge graph mapping entities including physicians, facilities, networks, procedures, reimbursement dynamics, and the relationships between them.

AcuityMD 的建立旨在解决这一问题的根本原因：医疗器械公司所需的商业洞察分散在理赔数据库、FDA 文件、政府记录和市场信号中，而任何一家医疗器械公司都无法单独整合这些信息。AcuityMD 将所有这些数据聚合到一个专有的医疗器械本体中：一个不断丰富的知识图谱，映射包括医生、医疗机构、网络、手术、报销动态以及它们之间关系的实体。

It aligns that ontology with each customer's internal data, including contracting information, product indications, territory structure, and CRM activity. The result is a unified, always updated view of the healthcare market for faster, smarter commercial execution..

它将该本体与每个客户的内部数据对齐，包括合同信息、产品适应症、地域结构和CRM活动。结果是形成了一个统一且始终更新的医疗市场视图，以实现更快速、更智能的商业执行。

AcuityAI, now available in open beta, is the AI built on that foundation. It connects AcuityMD’s ontology, a company’s business context, and each rep's specific situation to surface answers no horizontal AI platform can replicate. Reps spend less time figuring out where to go and more time in front of the right physicians, armed with the right context to win more business..

AcuityAI现已开放测试版，这款人工智能建立在该基础之上。它将AcuityMD的知识体系、企业的业务背景以及每位销售代表的具体情况相结合，提供任何横向AI平台都无法复制的答案。销售代表可以减少寻找目标的时间，更多时间用于接触合适的医生，并掌握赢得更多业务的正确背景信息。

'AcuityAI has given our commercial team sharper answers, faster,” said Mark Edwards, senior director of sales operations at Kuros Biosciences. “Insights that used to take hours are now surfaced right when our reps need them, leading to richer conversations and opportunities we might otherwise have missed.

“AcuityAI 让我们的商业团队获得了更精准、更快速的答案，”Kuros Biosciences 销售运营高级总监 Mark Edwards 表示，“以前需要花费数小时才能获得的洞察，现在正好在我们的代表需要时呈现出来，促成了更深入的对话和我们可能错过的机遇。”

One of our sales leaders asked AcuityAI for intel on a new national contract with a large health system, and quickly had a full business plan: where to go, which surgeons to prioritize, and more context than he could get spending hours on Google.”.

我们的一位销售主管向AcuityAI询问了一份与大型医疗系统新签的全国性合同的情报，很快就得到了一个完整的商业计划：该去哪里，优先考虑哪些外科医生，以及比他在谷歌上花数小时能获得的更多信息和背景。

AcuityMD’s new capital will fund three priorities: accelerate agentic AI capabilities for commercial personas, including sales reps, leadership and marketing teams; deepen the MedTech ontology that powers AcuityMD's data model; and expand the platform beyond commercial in pursuit of the company’s broader mission to accelerate the adoption of medical technology across the full product lifecycle..

AcuityMD 的新资本将用于三个重点方向：加速针对商业角色（包括销售代表、领导层和营销团队）的代理人工智能能力；深化支持 AcuityMD 数据模型的医疗技术本体；并将其平台扩展到商业领域之外，以追求公司更广泛的使命，即在整个产品生命周期中加速医疗技术的采用。

“AI will transform MedTech, but only with the right context, deeply embedded in the workflows where decisions are made. AcuityMD is that context layer, serving the rep in the field, the commercial leader planning territories, and the teams launching the next generation of innovation. I'm grateful to the hundreds of customers who have helped shape our platform,” concluded Mike Monovoukas, CEO and co-founder of AcuityMD.

“人工智能将改变医疗技术，但必须在正确的背景下，深度嵌入到决策制定的工作流程中。AcuityMD 就是这一背景层，服务于现场代表、规划区域的商业领袖以及推出下一代创新产品的团队。我非常感谢数百位帮助塑造我们平台的客户，”AcuityMD 首席执行官兼联合创始人 Mike Monovoukas 总结道。

“This funding accelerates our shared mission of accelerating adoption of cutting-edge medical technologies.”.

“这笔资金加速了我们共同推动尖端医疗技术应用的使命。”

About AcuityMD

关于AcuityMD

AcuityMD is the AI platform for MedTech trusted by over 400 MedTech companies – including 16 of the top 20. Commercial teams use AcuityMD to identify target markets, surface top opportunities, and grow their business. By combining real-world healthcare data with AI-powered insights, AcuityMD enables companies from pre-commercial to enterprise to understand where and how to sell faster to accelerate the adoption of medical technology.

AcuityMD 是备受400多家医疗技术公司信赖的AI平台，其中包括排名前20的16家公司。商业团队利用 AcuityMD 确定目标市场、挖掘最佳机会并发展业务。通过将真实世界中的医疗数据与人工智能驱动的洞察相结合，AcuityMD 帮助从商业化前到企业级的公司了解如何更快地销售，从而加速医疗技术的采用。

AcuityMD was named to Forbes’ 2025 “Next Billion-Dollar Startups” list – an elite group of 25 venture-backed U.S. companies identified as most likely to reach a $1 billion valuation..

AcuityMD 被评为福布斯2025年“下一个十亿美元初创企业”榜单的一员——这是由25家被认为最有可能达到10亿美元估值的美国风险投资支持公司组成的精英团体。

Contact:

联系：

Media Contact:

媒体联系人：

Lisa Barbadora, Barbadora INK for AcuityMD

丽莎·巴巴多拉，巴巴多拉INK为AcuityMD

+1 (610) 420-3413

+1 (610) 420-3413

lbarbadora@barbadoraink.com

lbarbadora@barbadoraink.com